The story appears on

Page A7

October 10, 2015

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Business » Finance

AbbVie invests in R&D for Chinese market

ABBVIE, a global biopharmaceutical firm, said the Chinese market is increasingly important and it will ensure its investment in research and development in its China division can cater to the domestic market.

“We are committed to the Chinese market,” said Scott Brun, vice president of AbbVie’s pharmaceutical development and research development, on a recent business trip in Shanghai.

“We will continue to expand our research team here, and increase the input in clinical development in particular, to get closer to Chinese patients.”

Last month, AbbVie officially established a Chinese team to drive development of pharmaceutical products to complement its research and development efforts.

AbbVie, a research-based pharmaceutical company focusing on drugs for rheumatoid arthritis, cancer, HIV, HCV and RSV infection, became independent in 2013 from health care firm Abbott.

In 2013, AbbVie set up its Chinese headquarters in Shanghai.

AbbVie has a number of clinical trials ongoing in China, including SONAR, a study evaluating a compound for use in slowing progression of diabetic kidney disease.


Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend